Pàgina inicial > Resultats de la cerca: Bevacizumab
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 6 registres trobats en 0.02 segons.
Articles, 6 registres trobats
Articles 6 registres trobats  
1.
11 p, 1.2 MB Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer : The avamet study / Vera, Ruth (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ; Gómez, María Luisa (Complejo Hospitalario de Navarra) ; Ayuso Colella, Juan Ramón (Hospital Clínic i Provincial de Barcelona) ; Figueras, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Martínez, Virginia (Hospital Universitario La Paz (Madrid)) ; Lacasta, Adelaida (Hospital de Donostia (Sant Sebastià, País Basc)) ; Ruiz-casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Safont, María José (Hospital General Universitario de Valencia) ; Aparicio Urtasun, Jorge (Hospital Universitari i Politècnic La Fe (València)) ; Campos, Juan Manuel (Hospital Arnau de Vilanova (València)) ; Cámara, Juan Carlos (Hospital Universitario Fundación Alcorcón) ; Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Montagut Viladot, Clara (Hospital del Mar (Barcelona, Catalunya)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Vieitez, Jose María (Hospital Universitario Central de Asturias) ; Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Jorge, Mónica (Hospital Xeral Cíes) ; Marín, Miguel (Hospital Clínico Universitario de la Arrixaca) ; Salgado, Mercedes (Complejo Hospitalario de Ourense) ; Viúdez, Antonio (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ; Universitat Autònoma de Barcelona
The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. [...]
2020 - 10.3390/cancers12082259
Cancers, Vol. 12 Núm. 8 (august 2020) , p. 1-12  
Registre complet - Creative Commons
2.
14 p, 1.4 MB Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer : a pilot clinical trial / Quintela-Fandino, Miguel (Hospital Universitario Quiron. Medical Oncology Department) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Morales, Serafin (Hospital Arnau de Vilanova (València)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Colomer, Ramon (Universidad Autónoma de Madrid. Facultad de Medicina) ; Apala, Juan V. (Hospital Universitario de Fuenlabrada ( Madrid)) ; Blanco, Raquel (Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology) ; Muñoz, Manuel (Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center) ; Caleiras, Eduardo (Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Iranzo, Vega (Universitat de València. Departament de Medicina) ; Martínez López, Mario (Hospital Universitario 12 de Octubre (Madrid)) ; Dominguez, Orlando (Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Hornedo, Javier (Hospital Universitario Quiron. Medical Oncology Department) ; Gonzalez-Cortijo, Lucia (Hospital Universitario Quiron. Medical Oncology Department) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Gasol Cudos, Ariadna (Hospital Arnau de Vilanova (València)) ; Malon, Diego (Hospital Universitario de Fuenlabrada ( Madrid)) ; Lopez-Alonso, Antonio (Spanish National Cancer Research Center) ; Moreno-Ortíz, María C. (Centro Nacional de Biotecnología/CSIC) ; Mouron, Silvana (Spanish National Cancer Research Center) ; Mañes, Santos (Centro Nacional de Biotecnología/CSIC) ; Universitat Autònoma de Barcelona
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. [...]
2020 - 10.1186/s13058-020-01362-y
Breast cancer research, Vol. 22 (november 2020)  
Registre complet - Creative Commons
3.
10 p, 324.7 KB Anti-angiogenic therapy for ovarian cancer / García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Marín Alcalá, Maria (Hospital Universitari de Vic) ; Martínez Vila, Clara (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona. Departament de Medicina
Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. [...]
2020 - 10.1016/j.ejcsup.2020.02.003
EJC Supplements, Vol. 15 (august 2020) , p. 77-86  
Registre complet - Creative Commons
4.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
Registre complet - Creative Commons
5.
16 p, 911.4 KB Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients / Molina García, David (Universidad de Castilla-La Mancha) ; Pérez Beteta, Julián (Universidad de Castilla-La Mancha) ; Martínez González, Alicia (Universidad de Castilla-La Mancha) ; Sepúlveda, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Peralta, Sergi (Hospital Universitari Sant Joan de Reus (Tarragona)) ; Gil-Gil, Miguel (Institut Català d'Oncologia) ; Reynes, Gaspar (Hospital Universitari i Politècnic La Fe (València)) ; Herrero, Ana (Hospital Universitario Miguel Servet (Saragossa)) ; de las Peñas, Ramon (Consorci Hospitalari Provincial de Castelló) ; Luque, Raquel (Hospital Universitario Virgen de las Nieves (Granada)) ; Capellades, Jaume (Hospital del Mar (Barcelona, Catalunya)) ; Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez García, Víctor M. (Universidad de Castilla-La Mancha)
Background: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. [...]
2016 - 10.1371/journal.pone.0161484
PloS one, Vol. 11 Núm. 8 (August 2016)  
Registre complet - Creative Commons
6.
15 p, 1.1 MB Pemetrexed/Carboplatin/Bevacizumab followed by maintenance Pemetrexed/Bevacizumab in hispanic patients with non-squamous non-small cell lung cancer: outcomes according to Thymidylate Synthase Expression / Cardona Zorrilla, Andrés Felipe (Clínica del Country (Bogotà, Colòmbia)) ; Rojas, Leonardo (Fundación de Investigación Clínica y Molecular en Cáncer (Bogotà, Colòmbia)) ; Wills, Beatriz (Clínica del Country (Bogotà, Colòmbia)) ; Arrieta, Oscar (Instituto Nacional de Cancerología (Ciutat de Mèxic)) ; Carranza, Hernán (Clínica del Country (Bogotà, Colòmbia)) ; Vargas, Carlos (Clínica del Country (Bogotà, Colòmbia)) ; Otero, Jorge (Clínica del Country (Bogotà, Colòmbia)) ; Cuello, Mauricio (Universidad de la República (Montevideo, Uruguai)) ; Corrales, Luis (Hospital San Juan de Dios (San José, Costa Rica)) ; Martín, Claudio (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Ortiz, Carlos (Clínica del Country (Bogotà, Colòmbia)) ; Franco Cirera, Sandra (Clínica del Country (Bogotà, Colòmbia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Objective: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. [...]
2016 - 10.1371/journal.pone.0154293
PloS one, Vol. 11 Núm. 5 (May 2016)  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem